Shares of clinical-stage biopharmaceutical company TC BioPharm Plc (NASDAQ:TCBP) are continuing to trade higher Wednesday after the company on Tuesday announced a strategic collaboration to advance gamma-delta T cells in oncology.

What Happened: TC BioPharm formed a three-year strategic collaboration with the University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.

The collaboration combines the clinical data of TC BioPharm's targeted gamma-delta T cell oncology pipeline and MD Anderson's clinical trial infrastructure and the translational research expertise of its immunotherapy platform.

The research teams are expected to work together on preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies, as well as to better understand the behaviors of the cells in patients.

"We are enthusiastic about working with MD Anderson to further our knowledge of gamma delta T cells in order to help TC Biopharm develop future trials and treatments using our platform therapy OmnImmune," said Bryan Kobel, CEO of TC BioPharm.

TC BioPharm shares are moving on abnormally high volume. The stock is trending across various social platforms and was the top trending ticker on Stocktwits at publication time.

TC BioPharm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. 

See Also: What's Going On With Moderna Stock Today?

TCBP Price Action: TC BioPharm shares are up 24.5% at $6.14 at time of publication, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.